TWI688393B - Manufacturing method of raw materials derived from amniotic membrane, manufacturing method of cosmetics, and manufacturing method of health food - Google Patents
Manufacturing method of raw materials derived from amniotic membrane, manufacturing method of cosmetics, and manufacturing method of health food Download PDFInfo
- Publication number
- TWI688393B TWI688393B TW107114430A TW107114430A TWI688393B TW I688393 B TWI688393 B TW I688393B TW 107114430 A TW107114430 A TW 107114430A TW 107114430 A TW107114430 A TW 107114430A TW I688393 B TWI688393 B TW I688393B
- Authority
- TW
- Taiwan
- Prior art keywords
- amniotic membrane
- placenta
- separation
- extract
- amniotic
- Prior art date
Links
- 210000001691 amnion Anatomy 0.000 title claims abstract description 366
- 239000002994 raw material Substances 0.000 title claims abstract description 84
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 37
- 235000013402 health food Nutrition 0.000 title claims abstract description 25
- 239000002537 cosmetic Substances 0.000 title claims abstract description 21
- 210000002826 placenta Anatomy 0.000 claims abstract description 117
- 239000000284 extract Substances 0.000 claims abstract description 95
- 238000000926 separation method Methods 0.000 claims abstract description 75
- 238000010257 thawing Methods 0.000 claims abstract description 53
- 238000007710 freezing Methods 0.000 claims abstract description 50
- 230000008014 freezing Effects 0.000 claims abstract description 50
- 238000000605 extraction Methods 0.000 claims abstract description 43
- 230000018044 dehydration Effects 0.000 claims abstract description 33
- 238000006297 dehydration reaction Methods 0.000 claims abstract description 33
- 238000005406 washing Methods 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 16
- 241000283086 Equidae Species 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 108090000145 Bacillolysin Proteins 0.000 claims description 7
- 108091005507 Neutral proteases Proteins 0.000 claims description 7
- 102000035092 Neutral proteases Human genes 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 239000000413 hydrolysate Substances 0.000 claims 2
- 230000003712 anti-aging effect Effects 0.000 abstract description 15
- 239000004615 ingredient Substances 0.000 abstract description 7
- -1 etc. Substances 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 27
- 239000007788 liquid Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 14
- 239000000843 powder Substances 0.000 description 13
- 238000010586 diagram Methods 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 230000035622 drinking Effects 0.000 description 9
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 8
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 description 8
- 235000013372 meat Nutrition 0.000 description 8
- 230000036548 skin texture Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000282887 Suidae Species 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 230000020411 cell activation Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 2
- 235000017491 Bambusa tulda Nutrition 0.000 description 2
- 241001330002 Bambuseae Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000011425 bamboo Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000037319 collagen production Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 235000001497 healthy food Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 108091005658 Basic proteases Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004993 mammalian placenta Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000037393 skin firmness Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/982—Reproductive organs; Embryos, Eggs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/204—Animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Developmental Biology & Embryology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Mycology (AREA)
- Birds (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Pregnancy & Childbirth (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本發明係提供一種萃取物等的製造方法、以及摻有該萃取物等的化妝品及健康食品，其中該方法係具有：分離前冷凍步驟(10)，係將採集之胎盤及羊膜冷凍；分離前解凍步驟(11)，係將胎盤及羊膜以流水解凍；分離前去水步驟(12)，係進行胎盤及羊膜的去水；分離步驟(13)，係將胎盤與羊膜分離；羊膜水洗步驟(14)，係對羊膜進行水洗；羊膜去水步驟(15)，係進行羊膜的去水；羊膜切碎步驟(16)，係將羊膜切碎；羊膜冷凍步驟(17)，係將羊膜冷凍；羊膜解凍步驟(18)，係將羊膜解凍；及萃取步驟(19)，係對羊膜進行分解萃取而得到萃取物；胎盤及羊膜係採用由馬所採集者，由此而該萃取物含有比習知源自胎盤之原料更多有用於抗老化效果的成分。The present invention provides a manufacturing method of extracts, etc., and cosmetics and health foods incorporating the extracts, etc., wherein the method has: a pre-separation freezing step (10), which freezes the collected placenta and amniotic membrane; before separation The thawing step (11) is to hydrolyze the placenta and amniotic membrane in flow; the dewatering step (12) before separation is to dehydrate the placenta and amniotic membrane; the separation step (13) is to separate the placenta and the amniotic membrane; the amniotic membrane washing step ( 14), the amniotic membrane is washed; the amniotic membrane dehydration step (15) is to remove the amniotic membrane; the amniotic membrane chopping step (16) is to shred the amniotic membrane; the amniotic membrane freezing step (17) is to freeze the amniotic membrane; The amniotic membrane thawing step (18) is to defrost the amniotic membrane; and the extraction step (19) is to decompose and extract the amniotic membrane to obtain an extract; the placenta and amniotic membrane are collected from horses, and the extract contains a source of conventional knowledge The raw materials from the placenta have more ingredients for anti-aging effect.
Description
本發明係有關於一種以人類、豬、馬或羊等哺乳動物的羊膜為原料的源自羊膜之原料的製造方法、以及摻有源自羊膜之原料的化妝品及健康食品。The present invention relates to a method for producing amniotic membrane-derived raw materials using amniotic membranes of humans, pigs, horses, or sheep and other mammals, as well as cosmetics and health foods incorporating amniotic membrane-derived raw materials.
向來，以哺乳動物的胎盤為來源原料之胎盤(placenta)萃取物等的源自胎盤之原料的製造方法已廣為人知。 例如專利文獻1中揭示一種由胎盤萃取物所構成之抗過敏劑的製造方法，其係將人類、牛、豬或羊的胎盤冷凍後弄碎，並予以熔解、水洗後，藉由離心或過濾進行脫水而得到脫水胎盤，對此脫水胎盤添加水、鹼蛋白酶等，藉由進行加熱、攪拌而引起酵素水解反應，進一步加熱後，將反應中止並於室溫放置一夜，採取上澄液加以過濾，將濾液以乙醇進行處理而形成乙醇溶出液，再將溶出液進行減壓濃縮後進行冷凍乾燥而作成粉末。 又，專利文獻2中揭示一種胎盤萃取物的製造方法，其係具有：將包含去除血液、污物及惡臭部位之經前處理的胎盤、與包含相對於前處理後的胎盤重量為0.2重量%～2重量%之蛋白酶的酵素裝入具可撓性之袋體後進行真空包裝之步驟；將經真空包裝之袋體，在以50MPa以上～未達200MPa之壓力，於20度～50度之範圍內控制成包含蛋白酶之酵素的最佳溫度的狀態下保持1日～3日之萃取步驟；及由袋體內的內容物分離出胎盤萃取物原液之固液分離步驟。 再者，專利文獻3中揭示一種胎盤萃取物的製造方法，其中以減少酵素消化過程中的繁複步驟為目的，而將人類或豬的胎盤，使用特定的耐熱性中性蛋白質分解酵素進行酵素消化。 [先前技術文獻] [專利文獻]Conventionally, methods for producing raw materials derived from placenta, such as placenta extracts using mammalian placenta as a raw material, have been widely known. For example,
[專利文獻1]日本特開2001-39879號公報 [專利文獻2]日本特開2011-160742號公報 [專利文獻3]日本特開2004-97033號公報[Patent Literature 1] Japanese Patent Application Publication No. 2001-39879 [Patent Literature 2] Japanese Patent Application Publication No. 2011-160742 [Patent Literature 3] Japanese Patent Application Publication No. 2004-97033
[發明所欲解決之課題][Problems to be solved by the invention]
源自胎盤之原料由於包含蛋白質、胺基酸、維生素、礦物質、酵素、核酸及成長因子(EGF等)等成分，而具有促進皮膚代謝、消除活性氧、肝機能強化、抗發炎作用及免疫賦活等抗老化效果，而活用於作為化妝品或健康食品等的原料。 然而，為提供抗老化效果更優良的化妝品或健康食品等，而期望開發出含有更多有用成分的萃取物等。The placenta-derived raw materials contain proteins, amino acids, vitamins, minerals, enzymes, nucleic acids and growth factors (EGF, etc.), which promote skin metabolism, eliminate active oxygen, strengthen liver function, anti-inflammatory effects and immunity It can be used as a raw material for cosmetics, health foods, etc. to revitalize anti-aging effects. However, in order to provide cosmetics and health foods with better anti-aging effects, it is desirable to develop extracts containing more useful ingredients.
因此，本發明係以提供一種含有比習知源自胎盤之原料更多有用於抗老化效果的成分的萃取物等的製造方法、以及摻有該萃取物等的化妝品及健康食品。 [解決課題之手段]Therefore, the present invention is to provide a method for producing an extract and the like containing more ingredients that have an anti-aging effect than conventional placenta-derived raw materials, and cosmetics and health foods incorporating the extract and the like. [Means to solve the problem]
請求項1記載之本發明之源自羊膜之原料的製造方法，其特徵為具有：分離前冷凍步驟，係將採集之胎盤及羊膜冷凍；分離前解凍步驟，係於前述分離前冷凍步驟後，將前述胎盤及前述羊膜以流水解凍；分離前去水步驟，係於前述分離前解凍步驟後，進行前述胎盤及前述羊膜的去水；分離步驟，係於前述分離前去水步驟後，將前述胎盤與前述羊膜分離；羊膜水洗步驟，係於前述分離步驟後，對前述羊膜進行水洗；羊膜去水步驟，係於前述羊膜水洗步驟後，進行前述羊膜的去水；羊膜切碎步驟，係於前述羊膜去水步驟後，將前述羊膜切碎；羊膜冷凍步驟，係於前述羊膜切碎步驟後，將前述羊膜冷凍；羊膜解凍步驟，係於前述羊膜冷凍步驟後，將前述羊膜解凍；及萃取步驟，係於前述羊膜解凍步驟後，對前述羊膜進行分解萃取而得到萃取物；前述萃取步驟係對前述羊膜添加純水及中性蛋白酶，且將萃取溫度設為30度以上70度以下、萃取時間設為1小時以上10小時以下，前述胎盤及前述羊膜為由馬所採集者。 請求項2記載之本發明之源自羊膜之原料的製造方法，其特徵為具有：分離前冷凍步驟，係將採集之胎盤及羊膜冷凍；分離前解凍步驟，係於前述分離前冷凍步驟後，將前述胎盤及前述羊膜以流水解凍；分離前去水步驟，係於前述分離前解凍步驟後，進行前述胎盤及前述羊膜的去水；分離步驟，係於前述分離前去水步驟後，將前述胎盤與前述羊膜分離；羊膜水洗步驟，係於前述分離步驟後，對前述羊膜進行水洗；羊膜去水步驟，係於前述羊膜水洗步驟後，進行前述羊膜的去水；羊膜切碎步驟，係於前述羊膜去水步驟後，將前述羊膜切碎；羊膜冷凍步驟，係於前述羊膜切碎步驟後，將前述羊膜冷凍；羊膜解凍步驟，係於前述羊膜冷凍步驟後，將前述羊膜解凍；及萃取步驟，係於前述羊膜解凍步驟後，對前述羊膜進行分解萃取而得到萃取物；前述萃取步驟係重複指定次數之前述羊膜的冷凍與熔解而分離出水溶性區分，前述胎盤及前述羊膜為由馬所採集者。 請求項3記載之本發明之化妝品的製造方法，其特徵為摻混藉由如請求項1或請求項2之源自羊膜之原料的製造方法所得之源自羊膜之原料。 請求項4記載之本發明之健康食品的製造方法，其特徵為摻混藉由如請求項1或請求項2之源自羊膜之原料的製造方法所得之源自羊膜之原料。 [發明之效果]The method for producing the amniotic membrane-derived raw material of the present invention described in
根據本發明，可提供一種含有比習知源自胎盤之原料更多有用於抗老化效果的成分的源自羊膜之原料的製造方法、以及摻有源自羊膜之原料的化妝品及健康食品。According to the present invention, it is possible to provide a method for producing an amniotic membrane-derived raw material containing more ingredients that have an anti-aging effect than a placenta-derived raw material, and a cosmetic and health food incorporating the amniotic membrane-derived raw material.
[實施發明之形態][Forms for carrying out the invention]
本發明第1實施形態之源自羊膜之原料的製造方法係具有：分離前冷凍步驟，係將採集之胎盤及羊膜冷凍；分離前解凍步驟，係於分離前冷凍步驟後，將胎盤及羊膜以流水解凍；分離前去水步驟，係於分離前解凍步驟後，進行胎盤及羊膜的去水；分離步驟，係於分離前去水步驟後，將胎盤與羊膜分離；羊膜水洗步驟，係於分離步驟後，對羊膜進行水洗；羊膜去水步驟，係於羊膜水洗步驟後，進行羊膜的去水；羊膜切碎步驟，係於羊膜去水步驟後，將羊膜切碎；羊膜冷凍步驟，係於羊膜切碎步驟後，將羊膜冷凍；羊膜解凍步驟，係於羊膜冷凍步驟後，將羊膜解凍；及萃取步驟，係於羊膜解凍步驟後，對羊膜進行分解萃取而得到萃取物；萃取步驟係對羊膜添加純水及中性蛋白酶，且將萃取溫度設為30度以上70度以下、萃取時間設為1小時以上10小時以下，胎盤及羊膜為由馬所採集者。 根據本實施形態，可提供一種含有比習知源自胎盤之原料更多有用於抗老化效果的成分的源自羊膜之原料。又，根據本實施形態，可有效地萃取出羊膜萃取物。The manufacturing method of the amniotic membrane-derived raw material according to the first embodiment of the present invention includes: a freezing step before separation, which freezes the collected placenta and amniotic membrane; a thawing step before separation, which follows the freezing step before separation, and the placenta and amniotic membrane Hydrolysis and freezing; dewatering step before separation, which is followed by the defrosting step before separation, to remove the placenta and amniotic membrane; separation step, which is after the dewatering step before separation, to separate the placenta from the amniotic membrane; amniotic membrane washing step, which is related to separation After the step, the amniotic membrane is washed; the amniotic membrane dehydration step is tied to the amniotic membrane washing step, and the amniotic membrane is dehydrated; the amniotic membrane chopping step is tied to the amniotic membrane dehydration step, and the amniotic membrane is shredded; the amniotic membrane freezing step is tied to After the amniotic membrane chopping step, the amniotic membrane is frozen; the amniotic membrane thawing step is tied to the amniotic membrane freezing step and the amniotic membrane is thawed; and the extraction step is after the amniotic membrane thawing step, the amniotic membrane is decomposed and extracted to obtain an extract; the extraction step is to The amniotic membrane is added with pure water and neutral protease, the extraction temperature is set to 30 degrees or more and 70 degrees or less, the extraction time is set to 1 hour or more and 10 hours or less, and the placenta and amniotic membrane are collected by horses. According to the present embodiment, a raw material derived from amniotic membrane can be provided that contains more ingredients that have an anti-aging effect than conventional raw materials derived from placenta. Furthermore, according to this embodiment, the amniotic membrane extract can be efficiently extracted.
本發明第2實施形態之源自羊膜之原料的製造方法係具有：分離前冷凍步驟，係將採集之胎盤及羊膜冷凍；分離前解凍步驟，係於分離前冷凍步驟後，將胎盤及羊膜以流水解凍；分離前去水步驟，係於分離前解凍步驟後，進行胎盤及羊膜的去水；分離步驟，係於分離前去水步驟後，將胎盤與羊膜分離；羊膜水洗步驟，係於分離步驟後，對羊膜進行水洗；羊膜去水步驟，係於羊膜水洗步驟後，進行羊膜的去水；羊膜切碎步驟，係於羊膜去水步驟後，將羊膜切碎；羊膜冷凍步驟，係於羊膜切碎步驟後，將羊膜冷凍；羊膜解凍步驟，係於羊膜冷凍步驟後，將羊膜解凍；及萃取步驟，係於羊膜解凍步驟後，對羊膜進行分解萃取而得到萃取物；萃取步驟係重複指定次數之羊膜的冷凍與熔解而分離出水溶性區分，胎盤及羊膜為由馬所採集者。 根據本實施形態，可提供一種含有比習知源自胎盤之原料更多有用於抗老化效果的成分的源自羊膜之原料。又，根據本實施形態，可有效地萃取出羊膜萃取物。The manufacturing method of the amniotic membrane-derived raw material according to the second embodiment of the present invention includes: a freezing step before separation, which freezes the collected placenta and amniotic membrane; a thawing step before separation, which follows the freezing step before separation, and the placenta and amniotic membrane Hydrolysis and freezing; dewatering step before separation, which is followed by the defrosting step before separation, to remove the placenta and amniotic membrane; separation step, which is after the dewatering step before separation, to separate the placenta from the amniotic membrane; amniotic membrane washing step, which is related to separation After the step, the amniotic membrane is washed; the amniotic membrane dehydration step is tied to the amniotic membrane washing step, and the amniotic membrane is dehydrated; the amniotic membrane chopping step is tied to the amniotic membrane dehydration step, and the amniotic membrane is shredded; the amniotic membrane freezing step is tied to After the amniotic membrane chopping step, the amniotic membrane is frozen; the amniotic membrane thawing step is tied to the amniotic membrane freezing step and the amniotic membrane is thawed; and the extraction step is after the amniotic membrane thawing step, the amniotic membrane is decomposed and extracted to obtain an extract; the extraction step is repeated The amniotic membrane is frozen and melted a specified number of times to separate the water-soluble distinction. The placenta and amniotic membrane are collected by horses. According to the present embodiment, a raw material derived from amniotic membrane can be provided that contains more ingredients that have an anti-aging effect than conventional raw materials derived from placenta. Furthermore, according to this embodiment, the amniotic membrane extract can be efficiently extracted.
本發明第3實施形態之化妝品的製造方法係摻混藉由如第1或第2實施形態之源自羊膜之原料的製造方法所得之源自羊膜之原料。 根據本實施形態，可提供一種抗老化效果優良的化妝品。The manufacturing method of the cosmetic of the 3rd embodiment of this invention mix|blends the raw material derived from the amniotic membrane obtained by the manufacturing method of the raw material derived from the amniotic membrane of the 1st or 2nd embodiment. According to the present embodiment, it is possible to provide a cosmetic having an excellent anti-aging effect.
本發明第4實施形態之健康食品的製造方法係摻混藉由如第1或第2實施形態之源自羊膜之原料的製造方法所得之源自羊膜之原料。 根據本實施形態，可提供一種抗老化效果優良的健康食品。 [實施例]The method for producing a health food according to a fourth embodiment of the present invention is blended with an amniotic membrane-derived raw material obtained by the method for producing an amniotic membrane-derived raw material according to the first or second embodiment. According to the present embodiment, it is possible to provide a health food excellent in anti-aging effect. [Example]
以下，就本發明一實施例之源自羊膜之原料的製造方法、以及摻有源自羊膜之原料的化妝品及健康食品加以說明。Hereinafter, a method for producing an amniotic membrane-derived raw material and an cosmetic and health food incorporating the amniotic membrane-derived raw material according to an embodiment of the present invention will be described.
圖1為本實施例之源自羊膜之原料的製造步驟圖。 本實施例之源自羊膜之原料(羊膜萃取物)的製造方法係具有分離前冷凍步驟10、分離前解凍步驟11、分離前去水步驟12、分離步驟13、羊膜水洗步驟14、羊膜去水步驟15、羊膜切碎步驟16、羊膜冷凍步驟17、羊膜解凍步驟18及萃取步驟19。FIG. 1 is a diagram of manufacturing steps of raw materials derived from amniotic membrane of the present embodiment. The manufacturing method of the amniotic membrane-derived raw material (amniotic membrane extract) of this embodiment has a pre-separation freezing
於分離前冷凍步驟10中，係將剛分娩後所採集之胎盤及羊膜立即以約-20度冷凍。經冷凍之胎盤及羊膜係運送至指定場所而保存。藉此，能以良好狀態保存採集之胎盤及羊膜。 此外，待採集之胎盤及羊膜，只要是人類、豬、馬或羊等哺乳類動物者即可；其中，較佳採用安全性優良，且適於化妝品及健康食品用途之豬或馬的胎盤及羊膜。In the
於分離前解凍步驟11中，係將在分離前冷凍步驟10中冷凍的胎盤及羊膜裝入容器中，並藉由對該容器沖水而將胎盤及羊膜急速解凍。分離前解凍步驟11係於即將開始分離步驟13前進行。 又，胎盤及羊膜經解凍後亦持續沖水。藉由持續沖水，可使接觸胎盤或羊膜的水常時維持潔淨狀態，而不會讓受血液等污染的解凍用水附著於胎盤或羊膜。藉此，可防止源自羊膜之原料影響化妝品或健康食品等最終製品的氣味或顏色。In the pre-separation thawing
於分離前去水步驟12中，係將在分離前解凍步驟11中解凍的胎盤及羊膜置入竹筐等去水容器中予以去水。藉此，可去除多餘的水分，而提升後續步驟中的作業性。In the dewatering
於分離步驟13中，係由在分離前去水步驟12中經去水的胎盤及羊膜中分離出羊膜。 胎盤及羊膜的形狀係因動物物種而異，例如，若為人類時，其構造為在子宮的一部分形成圓盤狀，所稱「盤狀胎盤」；若為豬及馬時，其構造為散佈於整個子宮內而形成，所稱「散佈性胎盤」。由胎盤分離羊膜時，若為人類的情況，由於胎盤形成一個大塊體，其作業甚為明確；而為散在性胎盤之豬及馬時則作業不甚明確，故按以下程序進行。 首先，將分離胎盤前的羊膜以剪刀等切斷工具剪開而予以伸展開來。其次，將胎盤與羊膜分離。其次，留意勿使附著於分離之羊膜的胎盤及血管殘留而予以去除。藉此，可將胎盤與羊膜有效地分離，而能夠僅將未附著有胎盤或血管的羊膜供予萃取。使用如此分離之羊膜經過萃取步驟19所得到的羊膜萃取物為含有更多有用於抗老化效果的成分的源自羊膜之原料。又，摻混於化妝品或健康食品等最終製品時，對最終製品之氣味或顏色造成的影響較少。In the
於羊膜水洗步驟14中，係對在分離步驟13中由胎盤分離的羊膜再度進行水洗。藉此，可更確實地防止胎盤或血管殘留於分離之羊膜。In the amniotic membrane washing
於羊膜去水步驟15中，係將在羊膜水洗步驟14中經過水洗的羊膜置入竹筐等去水容器中予以去水。藉由進行羊膜的水分去除，亦即羊膜的水分管理，可防止羊膜的重量因水分而參差不齊，而且可提升源自羊膜之原料的品質。 於羊膜去水步驟15後進行羊膜切碎步驟16。於羊膜切碎步驟16中經切碎的羊膜係再度進行去水。藉由再度進行去水，可提高水分管理的精確度，而進一步抑制羊膜重量的水分所造成的不均，而能夠進一步提升源自羊膜之原料的品質。In the amniotic
於羊膜切碎步驟16中，係將在羊膜去水步驟15中經去水的羊膜以絞碎機等的切碎機切碎成例如9mm見方。In the amniotic
於羊膜冷凍步驟17中，係測定在羊膜切碎步驟16中經切碎、去水的羊膜之重量後裝入塑膠袋等的收納容器中，排除空氣予以密封，迅速置入冷凍庫中以約-20度使羊膜冷凍。藉此，能以良好狀態保存切碎之羊膜。又，如上述，由於在羊膜去水步驟15及羊膜切碎步驟16中進行過水分管理，因此測得之羊膜的重量，可抑制水分所造成的不均。 此外，例如由馬的胎盤，可獲得以相對於分離前之胎盤的重量%計為約15%～40%重量的羊膜。 在羊膜冷凍步驟17中經冷凍的羊膜係於羊膜解凍步驟18中進行解凍。In the amniotic
於萃取步驟19中，係對在羊膜解凍步驟18中經解凍的羊膜，以酵素處理、水解處理、酸處理或冷凍熔解等方法進行分解萃取。藉此，可獲得羊膜萃取物。 藉由將萃取步驟19中所得之羊膜萃取物進行離心分離或過濾，可形成供摻混於化妝品或健康食品等的羊膜萃取物之液體原料。 又，藉由將萃取步驟19中所得之羊膜萃取物進行冷凍乾燥或噴霧乾燥，可形成供摻混於化妝品或健康食品等的羊膜萃取物之粉末原料。 藉由摻混指定量的羊膜萃取物之液體原料或粉末原料，可獲得摻有分離自胎盤之羊膜的萃取物的化妝品或健康食品。 此外，羊膜解凍步驟18後，未轉移至萃取步驟19，而是對經解凍之羊膜進行冷凍乾燥等乾燥予以粉碎時，可獲得羊膜之粉末原料。In the
圖2為表示藉由酵素免疫測定法定量根據圖1所示步驟所製造之羊膜萃取物的指標成分之結果的圖(單位：pg/g)。 指標成分係採用屬細胞激素類的Epidermal Growth Factor (EGF)、acidic Fibroblast Growth Factor (aFGF)、Hepatocyte Growth Factor (HGF)、Growth Differentiation Factor 11 (GDF-11)。Fig. 2 is a graph showing the results of quantifying the index components of the amniotic membrane extract produced by the procedure shown in Fig. 1 by an enzyme immunoassay (unit: pg/g). The index component system uses Epidermal Growth Factor (EGF), acidic Fibroblast Growth Factor (aFGF), Hepatocyte Growth Factor (HGF), Growth Differentiation Factor 11 (GDF-11), which are cytokines.
圖2(a)表示定量羊膜萃取物之粉末原料的指標成分之結果。羊膜萃取物之粉末原料為藉由在羊膜切碎步驟16中將羊膜切碎成碎肉狀後，經過羊膜冷凍步驟17及羊膜解凍步驟18，並於萃取步驟19中添加純水與中性蛋白酶，設萃取溫度為30度以上70度以下、萃取時間為1小時以上10小時以下進行處理，再將所得羊膜萃取物進行冷凍乾燥所製成者。以來源原料使用馬的羊膜的情形作為實施例1、使用豬的羊膜的情形作為實施例2。 又，圖2(a)中，作為比較例，一併示出定量胎盤萃取物之粉末原料的指標成分之結果。胎盤萃取物之粉末原料為除使用分離前的胎盤來替代羊膜以外係以與實施例1、2相同條件進行處理所製成者。以來源原料使用馬的胎盤的情形作為比較例1、使用豬的胎盤的情形作為比較例2。Fig. 2(a) shows the results of quantifying the index components of the powder raw material of the amniotic membrane extract. The powder material of amniotic membrane extract is obtained by chopping the amniotic membrane into minced meat in the amniotic
如圖2(a)所示，可知與比較例1、2相比，實施例1、2以較高值均衡地檢測出指標成分。尤其是就GDF-11，相對於在比較例1、2中未檢測出或即使檢測出亦為較低值，在實施例1、2中檢測出較高值。由於此等指標成分為有用於抗老化的成分，藉由摻混使用由胎盤分離之羊膜的羊膜萃取物之粉末原料，比起摻混使用分離羊膜前的胎盤或分離羊膜後的胎盤的胎盤萃取物之粉末原料時，更可提供抗老化效果優良的化妝品或健康食品。 又，就GDF-11，比起實施例2，實施例1為較高值。從而，欲含有較多的GDF-11時，較佳使用馬的羊膜萃取物之粉末原料。As shown in FIG. 2( a ), it can be seen that in Examples 1 and 2, the index components are detected with higher values in a balanced manner compared to Comparative Examples 1 and 2. In particular, GDF-11 has a lower value than that of Comparative Examples 1 and 2 that was not detected or even detected, and a higher value was detected in Examples 1 and 2. Since these index components are useful for anti-aging, by mixing the powdered raw material of amniotic membrane extract using amniotic membrane separated from placenta, the placenta extract using the placenta before separation of amniotic membrane or the placenta after amniotic membrane separation is blended. It can also provide cosmetics or health food with excellent anti-aging effect when it is used as a raw material. Furthermore, with regard to GDF-11, Example 1 has a higher value than Example 2. Therefore, when it is desired to contain more GDF-11, it is preferable to use the powder raw material of horse amnion extract.
圖2(b)表示定量羊膜萃取物之液體原料的指標成分之結果。羊膜萃取物之液體原料為藉由在羊膜切碎步驟16中將羊膜切碎成碎肉狀後，經過羊膜冷凍步驟17及羊膜解凍步驟18，並於萃取步驟19中重複指定次數之冷凍與熔解而分離出水溶性區分所製成者。以來源原料使用馬的羊膜的情形作為實施例3、使用豬的羊膜的情形作為實施例4。 又，圖2(b)中，作為比較例，一併示出定量胎盤萃取物之液體原料的指標成分之結果。胎盤萃取物之液體原料為除使用分離前的胎盤來替代羊膜以外係以與實施例3、4相同條件進行處理所製成者。以來源原料使用馬的胎盤的情形作為比較例3、使用豬的胎盤的情形作為比較例4。Fig. 2(b) shows the results of quantifying the index components of the liquid raw material of the amniotic membrane extract. The liquid raw material of the amniotic membrane extract is obtained by chopping the amniotic membrane into minced meat in the amniotic
如圖2(b)所示，可知與比較例3、4相比，實施例3、4以較高值均衡地檢測出指標成分。尤其是就GDF-11，相對於在比較例3、4中未檢測出或即使檢測出亦為較低值，在實施例3、4中檢測出較高值。由於此等指標成分為有用於抗老化的成分，藉由摻混使用由胎盤分離之羊膜的羊膜萃取物之液體原料，比起摻混使用分離羊膜前的胎盤或分離羊膜後的胎盤的胎盤萃取物之液體原料時，更可提供抗老化效果優良的化妝品或健康食品。 又，就GDF-11，比起實施例4，實施例3為較高值。從而，欲含有較多的GDF-11時，較佳使用馬的羊膜萃取物之液體原料。As shown in FIG. 2(b), it can be seen that in Examples 3 and 4, the index components are detected in a balanced manner at a higher value than in Comparative Examples 3 and 4. In particular, GDF-11 was detected at a lower value than that of Comparative Examples 3 and 4 or even detected, and a higher value was detected in Examples 3 and 4. Since these index components are useful for anti-aging, by mixing the liquid raw material using the amniotic membrane extract of the amniotic membrane separated from the placenta, the placenta extract using the placenta before separating the amniotic membrane or the placenta after separating the amniotic membrane is blended When it is a liquid raw material, it can also provide cosmetics or health food with excellent anti-aging effects. Furthermore, with regard to GDF-11, Example 3 has a higher value than Example 4. Therefore, when more GDF-11 is to be contained, it is preferable to use the liquid raw material of horse amnion extract.
圖3為表示根據圖1所示步驟所製造之羊膜萃取物的角質水分量保持數據的圖。橫軸為經過時間(min)、縱軸為角質水分量(μs)。 圖中「▲」為藉由在羊膜切碎步驟16中將馬的羊膜切碎成碎肉狀後，經過羊膜冷凍步驟17及羊膜解凍步驟18，並於萃取步驟19中添加純水與中性蛋白酶，設萃取溫度為30度以上70度以下、萃取時間為1小時以上10小時以下進行處理，再進行0.2μm的過濾所製成之羊膜萃取物的數據(實施例5)。 又，圖中「■」及「◆」為比較例的數據。「■」係表示對馬的胎盤進行處理所得之胎盤萃取物的數據(比較例5)；「◆」則表示未包含羊膜萃取物或胎盤萃取物的無添加之控制組(水)的數據(比較例6)。此外，比較例5之胎盤萃取物為除使用胎盤來替代羊膜以外係以與實施例5相同條件進行處理所製成者。FIG. 3 is a graph showing the horny moisture retention data of the amniotic membrane extract manufactured according to the procedure shown in FIG. 1. The horizontal axis is the elapsed time (min), and the vertical axis is the amount of horny water (μs). "▲" in the picture is by chopping the amniotic membrane of the horse into minced meat in the amniotic
如圖3所示，實施例5之羊膜萃取物在塗佈後90分鐘以後，與塗佈比較例5之胎盤萃取物的情形相比角質水分量較高，可知較比較例5之胎盤萃取物更有持續保濕力。As shown in FIG. 3, 90 minutes after the application of the amniotic membrane extract of Example 5, the horny water content is higher than that of the case of applying the placenta extract of Comparative Example 5, and it can be seen that the placenta extract of Comparative Example 5 More sustained moisturizing power.
圖4為表示根據圖1所示步驟所製造之羊膜萃取物的使用感試驗之結果的圖。 使用感試驗係針對摻有1%羊膜萃取物的化妝水，以10名受試者為對象進行一個月，就「濕潤」、「緊緻」、「光澤」及「柔軟」之各項目獲得評定。 使用於使用感試驗的羊膜萃取物為來源原料取馬的羊膜，藉由在羊膜切碎步驟16中將羊膜切碎成碎肉狀後，經過羊膜冷凍步驟17及羊膜解凍步驟18，並於萃取步驟19中添加純水與中性蛋白酶，設萃取溫度為30度以上70度以下、萃取時間為1小時以上10小時以下進行處理，再進行0.2μm的過濾所製成者。FIG. 4 is a graph showing the results of a feeling of use test of the amniotic membrane extract produced according to the procedure shown in FIG. 1. The sense of use test was conducted on a lotion containing 1% amniotic membrane extract for 10 months for 10 subjects, and was evaluated on the items of "wetness", "tightness", "gloss" and "softness" . The amniotic membrane extract used in the sensory test is used as the source material to obtain the amniotic membrane. After chopping the amniotic membrane into minced meat in the amniotic
如圖4所示，就「濕潤(保濕效果)」、「緊緻」、「光澤」及「柔軟」任一項皆可確認其提升效果。As shown in Figure 4, the lifting effect can be confirmed for any of "moisturizing (moisturizing effect)", "firming", "gloss" and "softness".
圖5為表示將根據圖1所示步驟所製造之羊膜萃取物塗佈於手背時之效果的圖(實施例6)。又，圖6為表示作為比較例將胎盤萃取物塗佈於手背時之效果的圖(比較例7)。再者，圖7為表示將根據圖1所示步驟所製造之羊膜萃取物塗佈於腳上時之效果的圖(實施例7)。 實施例6、7之羊膜萃取物為來源原料取馬的羊膜，藉由在羊膜切碎步驟16中將羊膜切碎成碎肉狀後，經過羊膜冷凍步驟17及羊膜解凍步驟18，並於萃取步驟19中添加純水與中性蛋白酶，設萃取溫度為30度以上70度以下、萃取時間為1小時以上10小時以下進行處理，再進行0.2μm的過濾所製成者。 又，比較例7之胎盤萃取物為除使用胎盤來替代羊膜以外係以與羊膜萃取物相同條件進行處理所製成者。 就其效果，以受試者A～E此5名作為塗佈羊膜萃取物組；以受試者F～J此5名作為塗佈胎盤萃取物組，以此等為對象，依以下程序進行5天來確認。 1.於塗佈前拍攝肌膚之肌理。 2.其後，以1天1次將羊膜萃取物或胎盤萃取物塗佈於手背。此外，就受試者A，亦將羊膜萃取物塗佈於其腳上。 3.於最後一天的同一時間再度拍攝肌膚之肌理。Fig. 5 is a diagram showing the effect when the amniotic membrane extract produced according to the procedure shown in Fig. 1 is applied to the back of a hand (Example 6). In addition, FIG. 6 is a diagram showing the effect when a placenta extract is applied to the back of a hand as a comparative example (Comparative Example 7). 7 is a figure which shows the effect when the amniotic membrane extract manufactured according to the process shown in FIG. 1 is applied to a foot (Example 7). The amniotic membrane extracts of Examples 6 and 7 are the raw materials. The amniotic membrane is taken from the raw material. After the amniotic membrane is shredded into minced meat in the amniotic
圖5及圖6係示出每位受試者的肌理狀態。圖5(a)～(e)係分別示出受試者A～E的肌理狀態；圖6(a)～(e)則分別表示受試者F～J的肌理狀態，於各(a)～(e)中，左側為塗佈前的肌理狀態、右側為最後一天的肌理狀態。 如圖5及圖6所示，將羊膜萃取物塗佈於手背的結果，確認能以與將胎盤萃取物塗佈於手背之結果同等或更高之程度提升肌膚紋理細緻度。5 and 6 show the texture state of each subject. Figures 5(a) to (e) show the texture state of subjects A to E, respectively; Figures 6 (a) to (e) show the texture state of subjects F to J, respectively, in each (a) In (e), the left side is the texture state before coating, and the right side is the texture state on the last day. As shown in Figs. 5 and 6, the results of applying the amniotic membrane extract to the back of the hand confirmed that the skin texture can be improved to the same or higher degree as the result of applying the placenta extract to the back of the hand.
圖7(a)中，就受試者A，左側為塗佈前的肌理狀態、右側為最後一天的肌理狀態。又，圖7(b)中，上層表示首日之塗佈前的肌膚狀態，下層表示最後一天的肌膚狀態。 如圖7(a)所示，將羊膜萃取物塗佈於腳上的結果，確認可改善肌膚乾燥並提升肌膚紋理細緻度。 又，如圖7(b)所示，將羊膜萃取物塗佈於腳上的結果，確認可改善濕疹。In FIG. 7(a), for the subject A, the left side is the texture state before coating, and the right side is the texture state on the last day. In addition, in FIG. 7(b), the upper layer indicates the skin condition before application on the first day, and the lower layer indicates the skin condition on the last day. As shown in Fig. 7(a), the result of applying the amniotic membrane extract to the feet confirmed that it can improve skin dryness and enhance the fineness of skin texture. Furthermore, as shown in FIG. 7(b), it was confirmed that the amniotic membrane extract was applied to the feet, and it was confirmed that eczema can be improved.
圖8為根據所圖1示步驟所製造之羊膜萃取物的飲用試驗之結果的圖。 飲用試驗係針對將馬的羊膜萃取物之粉末原料填充於硬膠囊而成的健康食品(實施例8)、與將馬的胎盤萃取物之粉末原料填充於硬膠囊而成的健康食品(比較例8)，以10名受試者為對象共計進行10天，就「適口度」、「氣味」、「身體狀況的良好變化」、「肌膚的濕潤度」、「肌膚的緊緻感・彈性」及「肌膚紋理」之各項目獲得評定。 使用於飲用試驗的羊膜萃取物之粉末原料為來源原料取馬的羊膜，藉由在羊膜切碎步驟16中將羊膜切碎成碎肉狀後，經過羊膜冷凍步驟17及羊膜解凍步驟18，並於萃取步驟19中添加純水與中性蛋白酶，設萃取溫度為30度以上70度以下、萃取時間為1小時以上10小時以下進行處理，再將所得羊膜萃取物進行冷凍乾燥所製成者。又，胎盤萃取物之粉末原料為除使用胎盤來替代羊膜以外係以與實施例8相同條件進行處理所製成者。 飲用試驗係依以下方法進行，就各項目請受試者選出實施例8與比較例8何者較優良。 第1組(5名受試者)：(1)飲用實施例8之健康食品5天→(2)飲用比較例8之健康食品5天(重複(1)與(2)至共計1個月) 第2組(5名受試者)：(1)飲用比較例8之健康食品5天→(2)飲用實施例8之健康食品5天(重複(1)與(2)至共計1個月)FIG. 8 is a graph of the drinking test results of the amniotic membrane extract manufactured according to the steps shown in FIG. 1. The drinking test is directed to a health food (Example 8) filled with powder materials of horse amniotic membrane extract in hard capsules and a health food (Comparative example) filled with powder materials of horse placenta extract in hard capsules 8) A total of 10 days for 10 subjects, including "palatableness", "smell", "good changes in physical condition", "skin moisture", "skin firmness and elasticity" And "Skin Texture" items were evaluated. The powder raw material of the amniotic membrane extract used in the drinking test is taken as the source raw material. After the amniotic membrane is shredded into minced meat in the amniotic
如圖8所示，實施例8之羊膜萃取物，就「適口度」、「氣味」及「肌膚的濕潤度」之項目可獲得與比較例8之胎盤萃取物同等的體感；就「身體狀況的良好變化」、「肌膚的緊緻感・彈性」及「肌膚紋理」，與比較例8的胎盤萃取物相比更可確認體感的提升效果。As shown in FIG. 8, the amniotic membrane extract of Example 8 can obtain the same body sensation as the placenta extract of Comparative Example 8 with respect to the items of “palatability”, “odor” and “skin moisture”; Compared with the placenta extract of Comparative Example 8, the "good change in condition", "the firmness and elasticity of the skin" and "skin texture" of the skin can be confirmed.
圖9為表示羊膜萃取物之液體原料所產生之細胞賦活作用的圖，圖9(a)表示針對表皮細胞之結果；圖9(b)表示針對真皮纖維母細胞之結果。橫軸為羊膜萃取物濃度(%)、縱軸為細胞活化率(%)。就圖9(a)及圖9(b)各者，左端示出未添加羊膜萃取物之控制組的數據作為比較例。 羊膜萃取物之液體原料為藉由在羊膜切碎步驟16中將羊膜切碎成碎肉狀後，經過羊膜冷凍步驟17及羊膜解凍步驟18，並於萃取步驟19中重複指定次數之冷凍與熔解而分離出水溶性區分所製成者。來源原料係使用馬的羊膜。FIG. 9 is a graph showing the cell activation effect produced by the liquid raw material of the amniotic membrane extract. FIG. 9(a) shows the results for epidermal cells; FIG. 9(b) shows the results for dermal fibroblasts. The horizontal axis is the concentration of amniotic membrane extract (%), and the vertical axis is the cell activation rate (%). For each of FIG. 9(a) and FIG. 9(b), the left end shows the data of the control group to which no amniotic membrane extract was added as a comparative example. The liquid raw material of the amniotic membrane extract is obtained by chopping the amniotic membrane into minced meat in the amniotic
如圖9所示，可知根據本實施例之製造方法所得之羊膜萃取物具有對表皮細胞、及真皮纖維母細胞的細胞賦活作用。As shown in FIG. 9, it can be seen that the amniotic membrane extract obtained according to the manufacturing method of this embodiment has a cell activation effect on epidermal cells and dermal fibroblasts.
圖10為表示羊膜萃取物之液體原料所產生之促進來自人類纖維母細胞之膠原蛋白產生之作用的圖。橫軸為羊膜萃取物濃度(%)、縱軸為膠原蛋白產生率(%)。左端示出未添加羊膜萃取物之控制組的數據作為比較例。 羊膜萃取物之液體原料為藉由在羊膜切碎步驟16中將羊膜切碎成碎肉狀後，經過羊膜冷凍步驟17及羊膜解凍步驟18，並於萃取步驟19中重複指定次數之冷凍與熔解而分離出水溶性區分所製成者。來源原料係使用馬的羊膜。Fig. 10 is a diagram showing the action of promoting the production of collagen from human fibroblasts by the liquid raw material of amniotic membrane extract. The horizontal axis is the concentration of amniotic membrane extract (%), and the vertical axis is the collagen production rate (%). The left end shows the data of the control group to which no amniotic membrane extract was added as a comparative example. The liquid raw material of the amniotic membrane extract is obtained by chopping the amniotic membrane into minced meat in the amniotic
如圖10所示，可知根據本實施例之製造方法所得之羊膜萃取物具有促進來自纖維母細胞之膠原蛋白產生之作用。 [產業上可利用性]As shown in FIG. 10, it can be seen that the amniotic membrane extract obtained according to the manufacturing method of this embodiment has an effect of promoting collagen production from fibroblasts. [Industry availability]
根據本發明之源自羊膜之原料的製造方法，可提供一種含有比習知源自胎盤之原料更多有用於抗老化效果的成分的源自羊膜之原料。又，可提供一種摻有此源自羊膜之原料的化妝品或健康食品等。According to the method for producing an amniotic membrane-derived raw material of the present invention, an amniotic membrane-derived raw material can be provided that contains more ingredients for anti-aging effects than conventional placenta-derived raw materials. In addition, a cosmetic or health food, etc. incorporating such raw material derived from amniotic membrane can be provided.
10‧‧‧分離前冷凍步驟11‧‧‧分離前解凍步驟12‧‧‧分離前去水步驟13‧‧‧分離步驟14‧‧‧羊膜水洗步驟15‧‧‧羊膜去水步驟16‧‧‧羊膜切碎步驟17‧‧‧羊膜冷凍步驟18‧‧‧羊膜解凍步驟19‧‧‧萃取步驟10‧‧‧Pre-separation freezing
圖1為本實施例之源自羊膜之原料的製造步驟圖。 圖2為表示定量該源自羊膜之原料的指標成分之結果的圖。 圖3為表示該源自羊膜之原料的角質水分量保持數據的圖。 圖4為表示該源自羊膜之原料的使用感試驗之結果的圖。 圖5為表示將該源自羊膜之原料塗佈於手背時之效果的圖。 圖6為表示作為該源自羊膜之原料的比較例將源自胎盤之原料塗佈於手背時之效果的圖。 圖7為表示將該源自羊膜之原料塗佈於腳上時之效果的圖。 圖8為表示該源自羊膜之原料的飲用試驗之結果的圖。 圖9為表示該羊膜萃取物之液體原料所產生之細胞賦活作用的圖。 圖10為表示該羊膜萃取物之液體原料所產生之促進來自人類纖維母細胞之膠原蛋白產生之作用的圖。FIG. 1 is a diagram of manufacturing steps of raw materials derived from amniotic membrane of the present embodiment. FIG. 2 is a graph showing the result of quantifying the index component of the raw material derived from amniotic membrane. FIG. 3 is a graph showing the retention data of the horny moisture content of the raw material derived from amniotic membrane. FIG. 4 is a graph showing the results of a feeling-of-use test of the raw material derived from amniotic membrane. FIG. 5 is a diagram showing the effect when the raw material derived from amniotic membrane is applied to the back of the hand. FIG. 6 is a diagram showing the effect when a raw material derived from placenta is applied to the back of a hand as a comparative example of the raw material derived from amniotic membrane. FIG. 7 is a diagram showing the effect when the amniotic membrane-derived raw material is applied to a foot. FIG. 8 is a graph showing the results of the drinking test of the raw material derived from amniotic membrane. FIG. 9 is a diagram showing the cell activation effect produced by the liquid raw material of the amniotic membrane extract. FIG. 10 is a diagram showing the action of promoting the production of collagen from human fibroblasts by the liquid raw material of the amniotic membrane extract.
Claims (4)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017-093908 | 2017-05-10 | ||
| JP2017093908A JP6373444B1 (en) | 2017-05-10 | 2017-05-10 | Amnion-derived raw material manufacturing method, cosmetic manufacturing method, and health food manufacturing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201900189A TW201900189A (en) | 2019-01-01 |
| TWI688393B true TWI688393B (en) | 2020-03-21 |
Family
ID=63165915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW107114430A TWI688393B (en) | 2017-05-10 | 2018-04-27 | Manufacturing method of raw materials derived from amniotic membrane, manufacturing method of cosmetics, and manufacturing method of health food |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JP6373444B1 (en) |
| KR (1) | KR102104196B1 (en) |
| CN (1) | CN109247011B (en) |
| RU (1) | RU2733542C1 (en) |
| TW (1) | TWI688393B (en) |
| WO (1) | WO2018207810A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6944606B1 (en) * | 2021-03-30 | 2021-10-06 | 新日本製薬株式会社 | Manufacturing method of cosmetic composition |
| JP2023101072A (en) | 2022-01-07 | 2023-07-20 | 株式会社ホルス | Method for producing extract, method for producing cosmetic, and method for producing substance for oral use |
| KR102503124B1 (en) * | 2022-08-18 | 2023-02-23 | 주식회사 에이바이오머티리얼즈 | Method for preparing sheep placenta extract containing high content of amino acid and cosmetic composition comprising the extract |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101316602A (en) * | 2005-09-27 | 2008-12-03 | 组织技术公司 | Amniotic membrane preparations and purified compositions and methods of use |
| CN104974980A (en) * | 2015-05-21 | 2015-10-14 | 重庆市细胞生物工程技术有限公司 | Human amniotic epithelial cell separation method |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2801313A1 (en) * | 1999-05-19 | 2001-05-25 | Coletica | COLLAGENIC PRODUCT CONTAINING COLLAGEN OF MARINE ORIGIN WITH LOW ODOR AND PREFERREDLY WITH IMPROVED MECHANICAL PROPERTIES, AS WELL AS ITS USE IN THE FORM OF COMPOSITIONS OR COSMETIC OR PHARMACEUTICAL PRODUCTS |
| JP2001039879A (en) | 1999-07-30 | 2001-02-13 | Koji Murata | Antiallergic agent obtained by purification of placenta extract and production of the allergic agent |
| JP2004097033A (en) * | 2002-09-05 | 2004-04-02 | Eiji Kimoto | Method for producing placental extract |
| WO2004026244A2 (en) * | 2002-09-18 | 2004-04-01 | Emiliano Ghinelli | Use of a human amniotic membrane composition for prophylaxis and treatment of diseases and conditions of the eye and skin |
| RU2252017C1 (en) * | 2004-06-22 | 2005-05-20 | Государственное образовательное учреждение высшего профессионального образования "Сибирский государственный технологический университет" | Cosmetic preparation and method for its obtaining |
| JP2006045070A (en) * | 2004-07-30 | 2006-02-16 | Hiroshi Hara | Tissue therapy by using placenta |
| KR101140573B1 (en) * | 2009-06-24 | 2012-05-02 | 농업회사법인 제주마산업 주식회사 | External Skin Preparation Using an Extract of Horse Plancenta |
| JP2011160742A (en) | 2010-02-12 | 2011-08-25 | Yamamoto Kenji | Method for producing placenta extract |
| US9290739B2 (en) * | 2010-09-08 | 2016-03-22 | Kang Stem Biotech Co., Ltd. | Equine amniotic fluid-derived multipotent stem cells and a method for producing the same |
| CN102225217A (en) * | 2011-06-23 | 2011-10-26 | 天津世纪康泰生物医学工程有限公司 | Preparation method of acellular dried active amnion |
| KR101906156B1 (en) * | 2011-11-22 | 2018-10-12 | 주식회사 강스템바이오텍 | Equine Amniotic Membrane-Derived Mesenchymal Stem Cells |
| CN103789258A (en) * | 2012-11-30 | 2014-05-14 | 陆华 | Separation method for human amniotic mesenchymal stem cells |
| EP2970882B1 (en) * | 2013-03-15 | 2018-11-28 | AlloSource | Cell repopulated collagen matrix for soft tissue repair and regeneration |
| CN103446184A (en) * | 2013-08-16 | 2013-12-18 | 南京医科大学 | Application of amniotic mesenchymal stem cells in preparation of medicine for prolonging life, health product or cosmetic |
| JP6282243B2 (en) * | 2015-03-11 | 2018-02-21 | 株式会社ホルス | Method for producing fermentation-aged placenta solution |
| MA45272A (en) * | 2015-06-27 | 2018-05-02 | Stimlabs Llc | AMNIOTIC FLUID PRODUCTS AND METHODS OF USE |
| CN105062959A (en) * | 2015-09-20 | 2015-11-18 | 领航干细胞再生医学工程有限公司 | Isolated culture method of human amnia mesenchymal stem cells |
-
2017
- 2017-05-10 JP JP2017093908A patent/JP6373444B1/en active Active
-
2018
- 2018-04-27 TW TW107114430A patent/TWI688393B/en active
- 2018-05-09 KR KR1020187035231A patent/KR102104196B1/en active IP Right Grant
- 2018-05-09 WO PCT/JP2018/017891 patent/WO2018207810A1/en active Application Filing
- 2018-05-09 RU RU2019114695A patent/RU2733542C1/en active
- 2018-05-09 CN CN201880000939.4A patent/CN109247011B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101316602A (en) * | 2005-09-27 | 2008-12-03 | 组织技术公司 | Amniotic membrane preparations and purified compositions and methods of use |
| CN104974980A (en) * | 2015-05-21 | 2015-10-14 | 重庆市细胞生物工程技术有限公司 | Human amniotic epithelial cell separation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109247011A (en) | 2019-01-18 |
| JP6373444B1 (en) | 2018-08-15 |
| KR20190005926A (en) | 2019-01-16 |
| WO2018207810A1 (en) | 2018-11-15 |
| CN109247011B (en) | 2021-11-23 |
| TW201900189A (en) | 2019-01-01 |
| RU2733542C1 (en) | 2020-10-05 |
| KR102104196B1 (en) | 2020-04-23 |
| JP2018188401A (en) | 2018-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102560013B1 (en) | Methods for Producing One or More Products of Interest from Insects by Chitin, Hydrolysates, and Enzymatic Hydrolysis | |
| US11884953B2 (en) | Method for preparing protein peptide based on connective tissue and prepared protein peptide and use thereof | |
| TWI688393B (en) | Manufacturing method of raw materials derived from amniotic membrane, manufacturing method of cosmetics, and manufacturing method of health food | |
| KR100977744B1 (en) | Collagen and method for producing same | |
| CN103205480A (en) | Method for producing high-quality collagen oligopeptide by using fish skin or fishbone | |
| CN109836474A (en) | It is a kind of to have effects that yak skin polypeptide tonified the blood and arrest bleeding and preparation method thereof | |
| CN105969830A (en) | Method for extracting active collagen peptide from pigskin | |
| CN101543257A (en) | Method for preparing pigskin collagen peptide | |
| JP5932783B2 (en) | Wrinkle improving composition containing placenta-derived component | |
| CN107114793A (en) | It is a kind of to comprehensively utilize the method that sturgeon bone prepares calcium and chondroitin sulfate | |
| CN109355337A (en) | Method for preparing active collagen polypeptide from fresh pigskin | |
| McBride et al. | The liquefaction of British Columbia herring by ensilage, proteolytic enzymes and acid hydrolysis | |
| CN104706561A (en) | Face cleansing cream | |
| RU2609635C1 (en) | Method for production of collagen protein from animal raw materials, collagen products and methods for use thereof | |
| CN106699838A (en) | Method for preparation of active protein peptide lyophilized powder from animal fetuses and placentas thereof | |
| CN109097426A (en) | A kind of preparation method of giant salamander protein peptides | |
| CN105255983A (en) | Extraction technology for collagen | |
| CN103992746B (en) | A kind of method utilizing the different gel strength pharmagel of Java tilapia skin preparation | |
| RU2718862C1 (en) | Fish scale processing method for production of functional beverage, functional food additive and cosmetic scrub | |
| US20190263891A1 (en) | Process for isolating bioactive biomolecules from animal by-products | |
| US20090022870A1 (en) | Method of manufacturing a transparent gelatin shape collagen food made with tendon and pettitoe of cow | |
| CN103947819A (en) | Method for extracting protein from pigskin | |
| WO2023132120A1 (en) | Method for producing extract, method for producing cosmetic, and method for producing substance for oral use | |
| RU2623146C1 (en) | Method for biologically active concentrate production from maral skin | |
| RU2559008C1 (en) | Method for preparation of small cattle paunche for usage during meat products manufacture |